Loading...
•
Dec 31, 2025
United Therapeutics Q4 2025 Earnings Report
United Therapeutics reported record fourth quarter 2025 revenue growth with higher net income driven by strong Tyvaso performance.
Key Takeaways
Fourth quarter 2025 revenue increased 7% year-over-year, led by continued growth in Tyvaso DPI and Orenitram, resulting in higher net income and solid operating profitability.
Total revenue grew to 790200000 from 735900000 year-over-year.
Total Tyvaso revenue increased 12% to 464300000, driven by Tyvaso DPI growth.
Net income rose to 364300000 from 301300000 in the prior year quarter.
Operating income remained strong at 356700000.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Management expressed confidence in continued double-digit revenue growth supported by Tyvaso momentum and upcoming clinical data readouts.
Positive Outlook
- Expectation to continue delivering double-digit revenue growth.
- Strong trajectory of Tyvaso DPI in expanding market.
- ADVANCE OUTCOMES and TETON-1 data readouts upcoming.
- Record total revenue for the fourth consecutive year.
- Strong commercial execution and market share gains.
Challenges Ahead
- Forward-looking statements subject to clinical trial risks.
- Revenue concentration in Tyvaso franchise.
- Potential regulatory and market uncertainties.
- Litigation risks remain ongoing.
- Results dependent on successful clinical outcomes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...